Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 4Phase NA 3Phase 1/2 3Phase 3 2

Status

Recruiting 3Completed 2Unknown 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 3Lymphoid 3Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 25Advanced Solid Tumors 18Breast Neoplasms 12Myelodysplastic Syndromes 11Neoplasms 10Advanced Solid Tumor 10Prostatic Neoplasms 9Solid Tumor 7Neoplasm Metastasis 7Multiple Myeloma 7Recurrence 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Stomach Neoplasms 4Small Cell Lung Carcinoma 4Melanoma 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Primary Myelofibrosis 2Nasopharyngeal Carcinoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Injections × Clear all
NCT05564650 2026-05-19

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Thomas Jefferson University

Phase 1 Completed
6 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT06565689 2026-02-05

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Excyte Biopharma Ltd

Phase 1 Recruiting
48 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Excyte Biopharma Ltd

Phase 1 Recruiting
70 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06082596 2023-10-13

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

BeBetter Med Inc

Phase 1 Completed
32 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT05631886 2023-08-28

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Chinese PLA General Hospital

Phase 1 Recruiting
10 enrolled
Lymphoid

Lymphoma, Neoplasm Metastasis, Recurrence

NCT05052970 2022-02-01

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 1 Unknown
60 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡